The patchwork rollout of a gene therapy exposes weaknesses in the pricing and regulatory frameworks that determine who ...

The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

Despite reported slowing of progression, regulators said the evidence on the novel oral agent blarcamesine did not support a ...

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting ...

Soybean oil is regarded as beneficial to health, but this study suggests that you can have too much of a good thing and ...

The decision applies to adolescents and adults and aligns with earlier US authorization for higher-risk groups.

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...

Dr Suchitra Sundaram shares key highlights on frontline time limited and all oral regimens producing deep MRD responses, ...

A 2025 report cowritten by Iyengar that quoted federal data, said that the 5-year DLBCL survival is approximately 80% in ...

The recommendation addresses a long-standing treatment gap for patients facing bladder removal after standard therapy fails.

According to editorialists, the study has the potential for major clinical impact, but more work is needed before guidelines ...